Monica Maria Pagliara1, Luca Tagliaferri2, Jacopo Lenkowicz3,4, Luigi Azario5,6, Dario Giattini7, Bruno Fionda2, Maria Grazia Sammarco1, Valentina Lancellotta2, Maria Antonietta Gambacorta2,4, Maria Antonietta Blasi1,8. 1. U.O.C. Oncologia Oculare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 2. U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 3. U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy jacopo.lenkowicz@unicatt.it. 4. Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy. 5. U.O.C. Fisica Sanitaria, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 6. Istituto di Fisica, Università Cattolica del Sacro Cuore, Rome, Italy. 7. Ophthalmology Clinic, Department of Medicine and Aging Science, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy. 8. Istituto di Oftalmologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Abstract
AIM: The aim of this study was to detect clinical factors predictive of loss of visual acuity after treatment in order to develop a predictive model to help identify patients at risk of visual loss. PATIENTS AND METHODS: This was a retrospective review of patients who underwent interventional radiotherapy (brachytherapy) with 106Ru plaque for primary uveal melanoma. A predictive nomogram for visual acuity loss at 3 years from treatment was developed. RESULTS: A total of 152 patients were selected for the study. The actuarial probability of conservation of 20/40 vision or better was 0.74 at 1 year, 0.59 at 3 years, and 0.54 at 5 years after treatment. Factors positively correlated with loss of visual acuity included: age at start of treatment (p=0.004) and longitudinal basal diameter (p=0.057), while distance of the posterior margin of the tumor from the foveola was inversely correlated (p=0.0007). CONCLUSION: We identified risk factors affecting visual function and developed a predictive model and decision support tool (AVATAR nomogram). Copyright
AIM: The aim of this study was to detect clinical factors predictive of loss of visual acuity after treatment in order to develop a predictive model to help identify patients at risk of visual loss. PATIENTS AND METHODS: This was a retrospective review of patients who underwent interventional radiotherapy (brachytherapy) with 106Ru plaque for primary uveal melanoma. A predictive nomogram for visual acuity loss at 3 years from treatment was developed. RESULTS: A total of 152 patients were selected for the study. The actuarial probability of conservation of 20/40 vision or better was 0.74 at 1 year, 0.59 at 3 years, and 0.54 at 5 years after treatment. Factors positively correlated with loss of visual acuity included: age at start of treatment (p=0.004) and longitudinal basal diameter (p=0.057), while distance of the posterior margin of the tumor from the foveola was inversely correlated (p=0.0007). CONCLUSION: We identified risk factors affecting visual function and developed a predictive model and decision support tool (AVATAR nomogram). Copyright
Authors: Lee M Jampol; Claudia S Moy; Timothy G Murray; Sandra M Reynolds; Daniel M Albert; Andrew P Schachat; Kenneth R Diddie; Robert E Engstrom; Paul T Finger; Kenneth R Hovland; Leonard Joffe; Karl R Olsen; Craig G Wells Journal: Ophthalmology Date: 2002-12 Impact factor: 12.079
Authors: Bertil Damato; Imran Patel; Ian R Campbell; Helen M Mayles; R Douglas Errington Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: J M Quivey; D H Char; T L Phillips; K A Weaver; J R Castro; S M Kroll Journal: Int J Radiat Oncol Biol Phys Date: 1993-07-15 Impact factor: 7.038
Authors: Luca Tagliaferri; Monica Maria Pagliara; Bruno Fionda; Andrea Scupola; Luigi Azario; Maria Grazia Sammarco; Rosa Autorino; Valentina Lancellotta; Silvia Cammelli; Carmela Grazia Caputo; Rafael Martinez-Monge; György Kovács; Maria Antonietta Gambacorta; Vincenzo Valentini; Maria Antonietta Blasi Journal: J Contemp Brachytherapy Date: 2019-02-28
Authors: Maria Antonietta Gambacorta; Vincenzo Valentini; Claudio Coco; Alberto Manno; Giovanni B Doglietto; Carlo Ratto; Maurizio Cosimelli; Francesco Miccichè; Francesca Maurizi; Luca Tagliaferri; Giovanna Mantini; Mario Balducci; Giuseppe La Torre; Brunella Barbaro; Aurelio Picciocchi Journal: Tumori Date: 2007 Mar-Apr
Authors: Luca Tagliaferri; Monica Maria Pagliara; Carlotta Masciocchi; Andrea Scupola; Luigi Azario; Gabriela Grimaldi; Rosa Autorino; Maria Antonietta Gambacorta; Antonio Laricchiuta; Luca Boldrini; Vincenzo Valentini; Maria Antonietta Blasi Journal: J Contemp Brachytherapy Date: 2017-12-30
Authors: Luca Tagliaferri; Ashwini Budrukkar; Jacopo Lenkowicz; Mauricio Cambeiro; Francesco Bussu; Jose Luis Guinot; Guido Hildebrandt; Bengt Johansson; Jens E Meyer; Peter Niehoff; Angeles Rovirosa; Zoltán Takácsi-Nagy; Luca Boldrini; Nicola Dinapoli; Vito Lanzotti; Andrea Damiani; Roberto Gatta; Bruno Fionda; Valentina Lancellotta; Tamer Soror; Rafael Martìnez Monge; Vincenzo Valentini; György Kovács Journal: J Contemp Brachytherapy Date: 2018-06-30